Imatinib Aurobindo

Imatinib, the active ingredient in Imatinib Aurobindo, is a tyrosine kinase inhibitor presented as a tablet for oral use. It is indicated for the treatment of chronic myeloid leukemia and gastrointestinal stromal tumor in adult patients. GNH USA supplies Imatinib Aurobindo as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres and pharmacies worldwide.

Imatinib targets abnormal tyrosine‑kinase signaling pathways that drive certain cancers. - Chronic myeloid leukemia (CML): helps achieve hematologic and cytogenetic remission by blocking BCR‑ABL activity. - Gastrointestinal stromal tumor (GIST): inhibits KIT‑driven tumor growth, improving progression‑free survival. - Philadelphia chromosome‑positive acute lymphoblastic leukemia (Ph+ ALL): suppresses BCR‑ABL signaling to support remission induction.

Imatinib may cause a range of adverse reactions that vary in frequency and severity.

Common Side Effects: - Nausea and vomiting - Fluid retention or peripheral edema - Muscle cramps or pain - Fatigue and weakness - Diarrhea or abdominal discomfort - Skin rash or pruritus

Serious or Rare Side Effects: - Severe neutropenia or leukopenia - Hepatotoxicity with elevated liver enzymes - Cardiac failure or reduced left‑ventricular function - Life‑threatening bleeding events - Interstitial lung disease or pulmonary fibrosis - Anaphylactic or severe hypersensitivity reactions

Before initiating therapy, clinicians should assess baseline health status and monitor for potential complications. - Blood count monitoring: perform complete blood counts regularly to detect cytopenias. - Liver function assessment: check hepatic enzymes before and during treatment. - Cardiac evaluation: consider baseline ECG and echocardiogram in patients with cardiac risk factors. - Hypersensitivity caution: discontinue if severe rash, angioedema, or anaphylaxis occurs. - Pregnancy and lactation: avoid use unless benefits clearly outweigh unknown risks. - Store at room temperature: keep in original packaging, protect from moisture and direct sunlight.

Imatinib can interact with other medicines, altering its efficacy or safety profile.

Major Interactions (Avoid): - Strong CYP3A4 inhibitors (e.g., ketoconazole, itraconazole) – may increase imatinib exposure. - Potent CYP3A4 inducers (e.g., rifampin, carbamazepine) – may reduce therapeutic levels. - Concomitant use with QT‑prolonging agents (e.g., sotalol) – heightens risk of cardiac arrhythmias.

Moderate Interactions (Monitor Closely): - Warfarin or other anticoagulants – may require INR monitoring. - CYP3A4 substrate drugs (e.g., midazolam) – may need dose adjustment. - Acid‑reducing agents (e.g., proton pump inhibitors) – could affect absorption; monitor clinical response.